Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease

Jianhua Chen, Xuemin Jian, Siyu Deng, Zengyi Ma, Xuefei Shou, Yue Shen, Qilin Zhang, Zhijian Song, Zhiqiang Li, Hong Peng, Cheng Peng, Min Chen, Cheng Luo, Dan Zhao, Zhao Ye, Ming Shen, Yichao Zhang, Juan Zhou, Aamir Fahira, Yongfei Wang, Shiqi Li, Zhaoyun Zhang, Hongying Ye, Yiming Li, Jiawei Shen, Hong Chen, Feng Tang, Zhenwei Yao, Zhifeng Shi, Chunjui Chen, Lu Xie, Ye Wang, Chaowei Fu, Ying Mao, Liangfu Zhou, Daming Gao, Hai Yan, Yao Zhao, Chuanxin Huang, Yongyong ShiNature Communications 2023 · DOI · OpenAlex

Introduction

This article serves as a formal correction to the 2018 study published in Nature Communications, which identified recurrent mutations in the USP48 and BRAF genes as significant drivers of Cushing’s disease. Cushing’s disease is characterized by the overproduction of cortisol, typically resulting from ACTH-secreting pituitary adenomas. The original research established that these specific genetic mutations contribute to the pathogenesis of the disease by altering cellular signaling pathways.

The Nature of the Correction

The necessity for this correction arose from a technical error in the assembly of Figure 2b. In the original publication, an immunohistochemistry (IHC) image for BRAF was inadvertently duplicated across two different panels. This update provides the correct IHC images to accurately represent the experimental evidence regarding protein expression and signaling activation in wild-type (WT) versus BRAF V600E-mutated pituitary samples.

Methods and Functional Analysis

The researchers utilized Immunohistochemistry (IHC) to visualize the localization and expression levels of key proteins within tissue sections. The corrected data focuses on three primary markers:

  1. ACTH: Used to confirm the identity of the hormone-producing cells central to Cushing’s disease.
  2. BRAF: To visualize the expression of the BRAF protein itself.
  3. p-Erk1/2: A marker for the phosphorylation (and thus activation) of the MAPK/ERK signaling pathway.

By comparing WT samples with those harboring the BRAF V600E mutation, the study demonstrates the functional consequences of the mutation on downstream signaling.

Key Results: Signaling Activation and Phenotypic Correlation

The corrected Figure 2b provides definitive visual and quantitative evidence of the impact of the BRAF V600E mutation.

Corrected Figure 2b showing IHC staining for ACTH, BRAF, and p-Erk1/2 in WT vs. BRAF V600E samples, with quantification of p-Erk1/2 positive cases.

Qualitative Observations

While ACTH staining remains consistent across both genotypes—confirming the relevant cell population—the p-Erk1/2 staining reveals a stark contrast. The BRAF V600E mutant samples exhibit significantly more intense and widespread staining for p-Erk1/2 compared to WT samples. This indicates that the mutation actively triggers the MAPK signaling pathway, a known driver of oncogenic growth.

Quantitative Distribution

The accompanying bar chart quantifies these observations across multiple cases. In WT samples, the majority of cases (6 out of 10) show negative (-) p-Erk1/2 staining, with only a small fraction showing high (++) levels. Conversely, in the BRAF V600E cohort, all cases show some level of activation, with the majority (3 out of 5) exhibiting high (++) positivity. This direct correlation between the genotype and the signaling phenotype reinforces the mutation's role as a functional driver of the disease.

Conclusion and Clinical Significance

While the correction addresses a visual assembly error, the fundamental scientific conclusions of the 2018 study remain unchanged. The validation of BRAF V600E as a driver of MAPK activation in Cushing’s disease is particularly significant for therapeutic development. Given that BRAF inhibitors are already successfully employed in treating other BRAF-mutated cancers, such as melanoma, these findings highlight a potential path toward precision medicine for patients with mutation-positive Cushing’s disease.

Summary updated

BibTeX
@inproceedings{chen2023author,
  author = {Jianhua Chen and Xuemin Jian and Siyu Deng and Zengyi Ma and Xuefei Shou and Yue Shen and Qilin Zhang and Zhijian Song and Zhiqiang Li and Hong Peng and Cheng Peng and Min Chen and Cheng Luo and Dan Zhao and Zhao Ye and Ming Shen and Yichao Zhang and Juan Zhou and Aamir Fahira and Yongfei Wang and Shiqi Li and Zhaoyun Zhang and Hongying Ye and Yiming Li and Jiawei Shen and Hong Chen and Feng Tang and Zhenwei Yao and Zhifeng Shi and Chunjui Chen and Lu Xie and Ye Wang and Chaowei Fu and Ying Mao and Liangfu Zhou and Daming Gao and Hai Yan and Yao Zhao and Chuanxin Huang and Yongyong Shi},
  title = {{Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-023-40833-6},
}
Figure